Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma

July 9, 2024

Read More

Obsidian Therapeutics Announces Appointment of William Pao, M.D., Ph.D., to Board of Directors

June 4, 2024

Read More

Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2024

Read More

We are pioneers in cell and gene therapy

Leading the next generation of engineered therapeutics

Our Platform

Our proprietary
cytoDRiVE platform

Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule

Read More


Join Our Team

Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.


Read More